Summary of Significant Accounting Policies - Segment Information (Details) |
3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|---|
|
Jun. 30, 2026
USD ($)
|
Mar. 31, 2026
USD ($)
|
Jun. 30, 2025
USD ($)
|
Mar. 31, 2025
USD ($)
|
Jun. 30, 2026
USD ($)
segment
|
Jun. 30, 2025
USD ($)
|
Dec. 31, 2025
USD ($)
|
|
| Segment Information | |||||||
| Number of reportable segments | segment | 1 | ||||||
| Operating expenses: | |||||||
| Total research and development | $ 3,246,519 | $ 2,569,943 | $ 5,916,298 | $ 5,006,941 | |||
| General and administrative expenses | 1,626,109 | 1,353,172 | 4,032,696 | 3,346,100 | |||
| IPR&D impairment | 9,190,897 | 9,190,897 | $ 0 | ||||
| Total operating expenses | 14,063,525 | 3,923,115 | 19,139,891 | 8,353,041 | |||
| Sublease income | (17,442) | (36,897) | |||||
| Loss on debt conversion with related party | 6,134,120 | ||||||
| Exchange loss, net | 30,569 | (4,532) | 36,429 | 18,742 | |||
| Net loss before income taxes | 11,529,609 | $ 4,986,614 | 3,807,353 | $ 10,924,952 | 16,516,223 | 14,732,305 | |
| Single reportable segment | |||||||
| Operating expenses: | |||||||
| Clinical | 2,301,995 | 1,630,084 | 4,111,415 | 3,447,316 | |||
| Chemical, manufacturing and controls | 505,131 | 558,916 | 770,856 | 694,038 | |||
| Research and preclinical | 731 | 8,094 | (4,903) | 32,228 | |||
| Regulatory | 4,663 | 5,628 | 19,325 | 27,286 | |||
| Other research and development costs | 433,999 | 367,221 | 1,019,605 | 806,073 | |||
| Total research and development | 3,246,519 | 2,569,943 | 5,916,298 | 5,006,941 | |||
| General and administrative expenses | 1,626,109 | 1,353,172 | 4,032,696 | 3,346,100 | |||
| IPR&D impairment | 9,190,897 | 9,190,897 | |||||
| Total operating expenses | 14,063,525 | 3,923,115 | 19,139,891 | 8,353,041 | |||
| Sublease income | (17,442) | (36,897) | |||||
| Loss on debt conversion with related party | 6,134,120 | ||||||
| Interest (income)/expense, net | (66,349) | (111,379) | (143,699) | 35,711 | |||
| Exchange loss, net | 30,569 | (4,532) | 36,429 | 18,742 | |||
| Net loss before income taxes | $ 14,010,303 | $ 3,807,204 | $ 18,995,724 | $ 14,541,614 | |||
| X | ||||||||||
- Definition Amount of expense for research and development relating to chemicals, manufacturing and controls. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and write-off of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development relating to research and pre-clinical. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and write-off of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development relating to clinical activities. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and write off of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development relating to regulatory activities. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and write-off of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. No definition available.
|
| X | ||||||||||
- Definition Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of impairment loss for indefinite-lived intangible asset. Excludes goodwill. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of interest income (expense) classified as operating. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of sublease income excluding finance and operating lease expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|